Cambrex Corporation (CBM) has completed an expansion of cGMP small-scale capacity at its Charles City, Iowa plant.
The project has seen the installation of two 500-gallon glass-lined reactors and creates a third small-scale work centre, further increasing flexibility for customer projects.
This latest investment follows the completion of an expansion of large-scale manufacturing capabilities and an announcement of the construction of a $24M, 4,500 sq. ft highly potent active pharmaceutical ingredient (HPAPI) manufacturing facility at Charles city, which is due to open in 2019.
Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.
Cambrex Corporation (CBM) has completed an expansion of cGMP small-scale capacity at its Charles City, Iowa plant.
The project has seen the installation of two 500-gallon glass-lined reactors and creates a third small-scale work centre, further increasing flexibility for customer projects.
This latest investment follows the completion of an expansion of large-scale manufacturing capabilities and an announcement of the construction of a $24M, 4,500 sq. ft highly potent active pharmaceutical ingredient (HPAPI) manufacturing facility at Charles city, which is due to open in 2019.
Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.
No comments:
Post a Comment